Pipeline

Passion for Discovery

pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.


CANDIDATE

Drug Discovery
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission

APPROVED
R/R AML
 
Phase 1 Dose-Escalation and Expansion Ongoing
 
EU
U.S.
Frontline AML Monotherapy
Phase 1 Dose-Escalation and Expansion
U.S.
IC Eligible Frontline AML
 
Phase 1b 7+3 Combo
IC Ineligible Frontline AML
 
Phase 1/2 Azacitidine Combo
Phase 3 AGILE Azacitidine Combo
Cholangio
 
 Phase 1 Dose-Escalation and Expansion
Phase 3 ClarlDHy
Glioma
 
Perioperative Study
Solid Tumors
Phase 1 Dose-Escalation and Expansion
Learn more about TIBSOVO®
R/R AML
 
Phase 3 IDHENTIFY
 EU
U.S.
IC Eligible Frontline AML
 
Phase 1b 7+3 Combo
IC Ineligible Frontline AML
 
Phase 1/2 Azacitidine Combo
Learn more about IDHIFA®
  • Celgene has worldwide development and commercialization rights.Agios has U.S. co–promotion and royalty rights.
Transfusion Independent PK Deficiency
 
Phase 2 DRIVE PK
Phase 3 ACTIVATE
Transfusion Dependent PK Deficiency
Phase 3 ACTIVATE-T
Thalassemia
Phase 2 Study
Learn more about Mitapivat
Glioma
 
Perioperative Study
Solid Tumors
Phase 1 Dose-Escalation and Expansion
Learn more about Vorasidenib
MTAP-Deleted Tumors
 
Phase 1 Dose-Escalation and Expansion
Learn more about AG-270
  • Subject to Celgene Option Joint Worldwide Collaboration.

IC = Intensive Chemotherapy

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.